Paul Andrew Gendron Acquires 5,000 Shares of InfuSystem (NYSE:INFU) Stock

InfuSystem Holdings, Inc. (NYSE:INFU) Director Paul Andrew Gendron bought 5,000 shares of InfuSystem stock in a transaction dated Friday, May 8th. The stock was acquired at an average cost of $8.88 per share, with a total value of $44,400.00. Following the completion of the acquisition, the director directly owned 70,000 shares of the company’s stock, valued at approximately $621,600. The trade was a 7.69% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

InfuSystem Stock Performance

Shares of NYSE INFU traded down $0.21 during midday trading on Tuesday, reaching $8.16. 244,052 shares of the company were exchanged, compared to its average volume of 135,464. The company has a current ratio of 1.98, a quick ratio of 1.59 and a debt-to-equity ratio of 0.50. InfuSystem Holdings, Inc. has a 1 year low of $5.08 and a 1 year high of $11.04. The stock has a fifty day simple moving average of $9.67 and a 200 day simple moving average of $9.21. The stock has a market cap of $164.76 million, a P/E ratio of 136.01 and a beta of 1.49.

Institutional Investors Weigh In On InfuSystem

A number of hedge funds and other institutional investors have recently bought and sold shares of INFU. Quarry LP purchased a new stake in shares of InfuSystem during the 4th quarter worth $31,000. Raymond James Financial Inc. purchased a new position in shares of InfuSystem in the 2nd quarter valued at about $33,000. Virtu Financial LLC acquired a new stake in shares of InfuSystem in the fourth quarter valued at about $90,000. LPL Financial LLC purchased a new stake in InfuSystem during the fourth quarter worth about $92,000. Finally, GK Wealth Management LLC purchased a new stake in InfuSystem during the fourth quarter worth about $95,000. Institutional investors and hedge funds own 71.13% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Roth Mkm reiterated a “buy” rating and issued a $15.00 target price (up from $14.00) on shares of InfuSystem in a research note on Tuesday, February 24th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $15.00.

About InfuSystem

InfuSystem Holdings Inc is a medical technology company that specializes in the rental, management and servicing of infusion pumps and associated devices used primarily for outpatient infusion therapy. The company provides a comprehensive suite of services that includes equipment delivery, setup and retrieval, preventive and corrective maintenance, reprocessing and quality assurance. InfuSystem’s offerings are designed to help hospitals, ambulatory surgery centers, oncology clinics and private infusion suites streamline clinical operations and maintain compliance with safety standards.

In addition to pump rental and repair services, InfuSystem has expanded into remote patient monitoring solutions.